• Norbert Lukan, Anna Hajdukova, Peter Kolarcik, and Vladimir Bella.
• Bratisl Med J. 2023 Jan 1; 124 (5): 363367363-367.

BackgroundClinical manifestation of secondary immunodeficiency is responsible for the decrease in lfe quality in cancer‑treated patients, which may result in administration delays, dose reductions, even in discontinuation of treatment. The main aim of presented study was to stress the possibility of influencing secondary infections with adjunctive immuno-regulatory medicament (AIRT).MethodsThe presented real-life retrospective study involved a cohort of 94 adult female patients aged from 30 to 87 years with mean age of 58.4 (SD = 11.37). The cohort was divided into two groups. One group (54 patients; 57.45 %) was treated by using the adjunctive immuno-regulatory medicaments and the other, control group (40 patients; 42.55 %), was without any immunological interventions in relation to secondary immunodeficiency. Patients in both groups were treated by standard oncotherapy.ResultsThe results show that in patients who were sent for immunological consultation, double-digit values of mild secondary infection frequencies were revealed. When immunologists decided to add adjunctive immunomodulatory medicament, the occurrence of infection and consumption of antibiotics decreased. The decrease was significant in the second evaluated interval (6th - 12th month).ConclusionsOur results strongly advise regular or even preventive examination of cancer patients by immunologic specialist for the purpose of attenuating some negative consequences of applied anti-tumor therapy (Tab. 1, Fig. 4, Ref. 14). Text in PDF www.elis.sk Keywords: secondary infection, breast cancer, real‑life study, clinical immunology, treatment.

22 keywords...

hide…